Investors

2023

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that it received notification on 10 October 2018 that Mrs Carol Anne Christie, wife of Mr Sean Christie, a Non-Executive Director of the Company, acquired 125,000 ordinary shares in the Company on 10 October 2018, representing 0.15% of the Company's issued share capital, at a price of 80 pence per share and will be held in the name of Mrs Carol Anne Christie. Prior to the transaction, neither Mr Christie nor Mrs Christie held ordinary shares in the Company.

Under the AIM Rules for Companies, Mrs Carol Anne Christie is considered a related party and therefore this transaction or any further transactions must be disclosed under the AIM Rules for Companies.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 and the person who arranged for release of this announcement on behalf of the Company was Stephen O'Hara, Chief Executive.

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

2022

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that it received notification on 10 October 2018 that Mrs Carol Anne Christie, wife of Mr Sean Christie, a Non-Executive Director of the Company, acquired 125,000 ordinary shares in the Company on 10 October 2018, representing 0.15% of the Company's issued share capital, at a price of 80 pence per share and will be held in the name of Mrs Carol Anne Christie. Prior to the transaction, neither Mr Christie nor Mrs Christie held ordinary shares in the Company.

Under the AIM Rules for Companies, Mrs Carol Anne Christie is considered a related party and therefore this transaction or any further transactions must be disclosed under the AIM Rules for Companies.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 and the person who arranged for release of this announcement on behalf of the Company was Stephen O'Hara, Chief Executive.

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

2021

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that it received notification on 10 October 2018 that Mrs Carol Anne Christie, wife of Mr Sean Christie, a Non-Executive Director of the Company, acquired 125,000 ordinary shares in the Company on 10 October 2018, representing 0.15% of the Company's issued share capital, at a price of 80 pence per share and will be held in the name of Mrs Carol Anne Christie. Prior to the transaction, neither Mr Christie nor Mrs Christie held ordinary shares in the Company.

Under the AIM Rules for Companies, Mrs Carol Anne Christie is considered a related party and therefore this transaction or any further transactions must be disclosed under the AIM Rules for Companies.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 and the person who arranged for release of this announcement on behalf of the Company was Stephen O'Hara, Chief Executive.

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

2020

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that it received notification on 10 October 2018 that Mrs Carol Anne Christie, wife of Mr Sean Christie, a Non-Executive Director of the Company, acquired 125,000 ordinary shares in the Company on 10 October 2018, representing 0.15% of the Company's issued share capital, at a price of 80 pence per share and will be held in the name of Mrs Carol Anne Christie. Prior to the transaction, neither Mr Christie nor Mrs Christie held ordinary shares in the Company.

Under the AIM Rules for Companies, Mrs Carol Anne Christie is considered a related party and therefore this transaction or any further transactions must be disclosed under the AIM Rules for Companies.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 and the person who arranged for release of this announcement on behalf of the Company was Stephen O'Hara, Chief Executive.

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

2019

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that it received notification on 10 October 2018 that Mrs Carol Anne Christie, wife of Mr Sean Christie, a Non-Executive Director of the Company, acquired 125,000 ordinary shares in the Company on 10 October 2018, representing 0.15% of the Company's issued share capital, at a price of 80 pence per share and will be held in the name of Mrs Carol Anne Christie. Prior to the transaction, neither Mr Christie nor Mrs Christie held ordinary shares in the Company.

Under the AIM Rules for Companies, Mrs Carol Anne Christie is considered a related party and therefore this transaction or any further transactions must be disclosed under the AIM Rules for Companies.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 and the person who arranged for release of this announcement on behalf of the Company was Stephen O'Hara, Chief Executive.

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

2018

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that it received notification on 10 October 2018 that Mrs Carol Anne Christie, wife of Mr Sean Christie, a Non-Executive Director of the Company, acquired 125,000 ordinary shares in the Company on 10 October 2018, representing 0.15% of the Company's issued share capital, at a price of 80 pence per share and will be held in the name of Mrs Carol Anne Christie. Prior to the transaction, neither Mr Christie nor Mrs Christie held ordinary shares in the Company.

Under the AIM Rules for Companies, Mrs Carol Anne Christie is considered a related party and therefore this transaction or any further transactions must be disclosed under the AIM Rules for Companies.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 and the person who arranged for release of this announcement on behalf of the Company was Stephen O'Hara, Chief Executive.

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.